Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Olmesartan medoxomil
Drug ID BADD_D01603
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code C09CA08
DrugBank ID Not Available
KEGG ID D01204
MeSH ID D000068557
PubChem ID 130881
TTD Drug ID D07UBG
NDC Product Code 62331-056; 64552-4028; 65841-168; 65862-708; 66039-824; 68554-0069; 13668-248; 16729-320; 63629-9426; 68462-438; 71205-174; 72189-137; 62512-0034; 65862-742; 13668-249; 27808-277; 50090-3655; 65162-081; 0527-2426; 70518-2347; 71205-459; 0713-0860; 0713-0861; 65691-0071; 66577-050; 33342-180; 50090-3487; 50228-341; 51407-199; 62332-131; 62332-132; 65862-743; 70518-2127; 70771-1060; 71205-458; 63629-8525; 65862-741; 67877-447; 70771-1059; 15894-0019; 65372-1171; 27808-275; 43547-301; 49252-065; 65162-079; 65597-103; 65597-104; 68382-643; 12666-0021; 64220-123; 66003-104; 16729-322; 43547-300; 46708-132; 46708-133; 62332-133; 63629-8524; 71205-172; 72189-373; 52562-011; 43547-299; 46708-131; 50090-3656; 51407-197; 65162-080; 67877-445; 49587-110; 66003-103; 16729-321; 42571-201; 50228-339; 51407-198; 63629-8523; 67877-446; 68382-645; 0527-2427; 70756-808; 71335-0775; 71335-1920; 0713-0862; 42571-202; 63629-8522; 68462-436; 70756-809; 71335-0817; 71335-0999; 14501-0011; 52038-003; 52038-006; 65015-676; 66577-019; 50228-340; 65597-101; 68382-644; 68462-437; 0527-2425; 70756-810; 70771-1061; 72189-138; 66003-101; 66039-944; 82245-0206; 13668-250; 27808-276; 33342-178; 33342-179; 42571-203; 49252-066; 49252-067
UNII 6M97XTV3HD
Synonyms Olmesartan Medoxomil | Medoxomil, Olmesartan | 5-Methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346 | Benicar | Olmetec | CS 866 | CS-866 | CS866 | Votum
Chemical Information
Molecular Formula C29H30N6O6
CAS Registry Number 144689-63-4
SMILES CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Alopecia23.02.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Blood bilirubin13.03.04.015--Not Available
Blood bilirubin increased13.03.04.018--
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood triglycerides increased13.12.03.001--Not Available
Blood uric acid increased13.02.04.001--Not Available
Bone pain15.02.01.001--
Bronchitis22.07.01.001; 11.01.09.001--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Cough22.02.03.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspepsia07.01.02.001--
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.004--
Fatigue08.01.01.002--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal pain07.01.05.005--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
Hypercholesterolaemia14.08.01.001--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages